+44 7868 792050
Department of Medical Oncology, Fox Chase Cancer Center
Igor Astsaturov, Assistant member from Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia. He has done Internship and Residency in Internal Medicine, Good Samaritan Hospital, Baltimore, MD and PhD in Hematology/Oncology, Russian Hematological Research Center, Moscow.
Intrinsic and acquired cellular resistance limits the efficacy of EGFR targeted cancer therapeutics. Rational and more efficacious combinations of targeted therapeutics, siRNA screening to comparatively probe the signaling network for proteins that regulate the effectiveness of both targeted (EGFR being the prime target) and chemotherapeutic agents, New synergistic targets with EGFR antagonists as a direct path to clinical exploitation of study results including distal sterol biosynthesis pathway metabolic enzymes such as SC4MOL and NSDHL using cellular systems and an animal model of conditional NSDHL deficiency. Explorations of new metabolic targets for cancer therapy involving these previously unexplored sterol pathway genes.